Calquence (acalabrutinib)

pCPA File Number: 21416
Negotiation Status:
Active Negotiation
Indication(s):
Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate
Sponsor/Manufacturer:
ASTRAZENECA CANADA INC
CADTH Project Number:
PC0210-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable